3-108563157-C-T
Position:
Variant summary
Our verdict is Uncertain significance. Variant got 3 ACMG points: 3P and 0B. PM2PP3
The NM_020890.3(CIP2A):c.1603G>A(p.Ala535Thr) variant causes a missense change. The variant allele was found at a frequency of 0.00000248 in 1,611,860 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★).
Frequency
Genomes: 𝑓 0.000020 ( 0 hom., cov: 32)
Exomes 𝑓: 6.9e-7 ( 0 hom. )
Consequence
CIP2A
NM_020890.3 missense
NM_020890.3 missense
Scores
5
7
7
Clinical Significance
Conservation
PhyloP100: 7.00
Genes affected
CIP2A (HGNC:29302): (cellular inhibitor of PP2A) Enables protein homodimerization activity. Predicted to act upstream of or within positive regulation of neural precursor cell proliferation and spermatogenesis. Located in cytosol and plasma membrane. [provided by Alliance of Genome Resources, Apr 2022]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Uncertain_significance. Variant got 3 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
PP3
MetaRNN computational evidence supports a deleterious effect, 0.789
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CIP2A | NM_020890.3 | c.1603G>A | p.Ala535Thr | missense_variant | 13/21 | ENST00000295746.13 | NP_065941.2 | |
CIP2A | XM_006713716.4 | c.1600G>A | p.Ala534Thr | missense_variant | 13/21 | XP_006713779.1 | ||
CIP2A | XM_011513057.3 | c.661G>A | p.Ala221Thr | missense_variant | 6/14 | XP_011511359.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CIP2A | ENST00000295746.13 | c.1603G>A | p.Ala535Thr | missense_variant | 13/21 | 1 | NM_020890.3 | ENSP00000295746 | P1 | |
CIP2A | ENST00000491772.5 | c.1126G>A | p.Ala376Thr | missense_variant | 13/21 | 1 | ENSP00000419487 | |||
CIP2A | ENST00000487834.5 | n.1872G>A | non_coding_transcript_exon_variant | 13/14 | 1 | |||||
CIP2A | ENST00000481530.5 | c.*1173G>A | 3_prime_UTR_variant, NMD_transcript_variant | 13/21 | 1 | ENSP00000417297 |
Frequencies
GnomAD3 genomes AF: 0.0000197 AC: 3AN: 152038Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
3
AN:
152038
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.00000399 AC: 1AN: 250698Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 135464
GnomAD3 exomes
AF:
AC:
1
AN:
250698
Hom.:
AF XY:
AC XY:
0
AN XY:
135464
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 6.85e-7 AC: 1AN: 1459822Hom.: 0 Cov.: 30 AF XY: 0.00 AC XY: 0AN XY: 726268
GnomAD4 exome
AF:
AC:
1
AN:
1459822
Hom.:
Cov.:
30
AF XY:
AC XY:
0
AN XY:
726268
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000197 AC: 3AN: 152038Hom.: 0 Cov.: 32 AF XY: 0.0000135 AC XY: 1AN XY: 74250
GnomAD4 genome
AF:
AC:
3
AN:
152038
Hom.:
Cov.:
32
AF XY:
AC XY:
1
AN XY:
74250
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Bravo
AF:
ExAC
AF:
AC:
1
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Nov 08, 2022 | The c.1603G>A (p.A535T) alteration is located in exon 13 (coding exon 13) of the KIAA1524 gene. This alteration results from a G to A substitution at nucleotide position 1603, causing the alanine (A) at amino acid position 535 to be replaced by a threonine (T). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Uncertain
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Pathogenic
DANN
Pathogenic
DEOGEN2
Benign
T;.;T
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Pathogenic
D
LIST_S2
Uncertain
D;D;D
M_CAP
Benign
D
MetaRNN
Pathogenic
D;D;D
MetaSVM
Benign
T
MutationAssessor
Uncertain
M;.;.
MutationTaster
Benign
D;D
PrimateAI
Uncertain
T
PROVEAN
Benign
N;N;.
REVEL
Uncertain
Sift
Uncertain
D;D;.
Sift4G
Uncertain
D;D;D
Polyphen
D;.;.
Vest4
MutPred
Loss of glycosylation at P539 (P = 0.0521);.;.;
MVP
MPC
ClinPred
D
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at